Rna Diagnostics Inc. is clinical stage molecular diagnostics company for personalized cancer therapy management. Our technology, Veridapt DX, is a precision oncology biomarker platform that identifies patients who are not responding to breast cancer treatment as early as 5 weeks into chemotherapy. This enables physicians to rapidly optimize treatment decisions and avoid ineffective therapies for better patient outcomes with fewer toxic side effects. The market for Veridapt DX in early breast cancer exceeds $2B: ● Breakthrough Oncology Technology: Early identification of non-responding cancer patients to improve treatment strategies and reduce toxicity. ● Strong Clinical Validation: Supported by data from over 1,000 patients with a 93% Negative Predictive Value (NPV) from Phase 1 of validation trial (BREVITY). ● BREVITY Pivotal Study: Read out of results from a prospective international trial of over 700 patients expected in Q2 2026. ● Capital Efficiency & De-Risked Science: Over $20M raised, 10+ years of development, and a near-term clinical trial completion. ● No FDA hurdles: Clear path to market and reimbursement with (LDT) business model from CLIA-certified lab ● High M&A Interest: Engaged discussions with major diagnostics firms like Hologic, Quest, and Exact Sciences. iGan Partners, Toronto, is leading the Series B financing.